Motif Bio Plc Get updated coverage from Zeus Capital

Motif Bio Plc (LON:MTFB) is the topic of conversation when DirectorsTalk caught up with Dr Gary Waanders the Director of Healthcare Research at Zeus Capital. Gary covers the highlights for us, points out the key events we should be focussing on over the next 12 months and explains how Motif Bio’s valuation compares to its peers.


Motif Bio Plc is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.

You might also enjoy reading  Surface Transforms analyst Zeus upgrades forecasts

Share this interview

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp
Motif Bio plc
Motif Bio Plc Get updated coverage from Zeus Capital

Other Interviews

More News

Ask your questions

Do you have questions you’d like to ask this company, get in touch and we’ll ask them for you.   

I have questions